L-Nutra CEO Dr Joseph Antoun has been named a 2026 Life Sciences Visionary by LA Times Studios for advancing longevity as a clinical discipline. The recognition highlights his work transforming healthcare from reactive treatment to prevention-focused care centred on metabolic health and healthy aging. Under Antoun's leadership, L-Nutra has generated over $250 million in revenue and built a portfolio of 221 licensed patents in longevity-focused nutrition. The company recently demonstrated that fasting-mimicking nutrition can activate autophagy and cellular rejuvenation in humans, translating Nobel Prize-winning research into practical applications. L-Nutra partners with medical centres to deliver nutrition therapies addressing chronic conditions including diabetes and cardiovascular disease. Antoun also serves as Co-Director of the Center for Health Policy at the University of Chicago.

L-Nutra named Innovator Partner for the Longevity Show 2026. Precision nutrition pioneer L-Nutra will bring fasting-mimicking science and clinically validated longevity programs to the Longevity Show. The Longevity Show 2026 has announced L-Nutra as an Innovator Partner, signaling the rising influence of evidence-based nutrition in extending healthspan and tackling the chronic diseases of aging. Nutrition has always been medicine's awkward middle child - everywhere at once, yet oddly ignored. We've seen it relegated to flimsy patient pamphlets or over-analyzed in academic journals, but it's rarely been treated with the kind of systematic, pharmaceutical-grade discipline that actually moves the needle. Nutrition as infrastructure. Andrea Ghirardi, L-Nutra's CEO EMEA, isn't heading to the Business Stage to talk about lifestyle tweaks or wellness trends. Instead, he's framing precision nutrition as a piece of essential infrastructure - a strategic necessity for societies that are rapidly graying. This shift from 'nice-to-have' to 'must-hire' continues in a closed-door roundtable, where industry leaders will hammer out how to actually bake metabolic resilience into formal healthcare. For those who want to see the mechanics in action, L-Nutra's floor presence moves past the white papers to show how fasting-mimicking and medical nutrition programs work in practice. Behind the brand sits a formidable evidence base. In partnership with 18 global university research centers, L-Nutra has developed formulations inspired by precision nutrition and powered by cellular longevity science; programs supported by 47 clinical trials and protected by 137 granted patents. Numbers matter here - because in a sector crowded with biohacks and bravado, validation is currency. Metabolic levers, pulled on purpose. The engine driving L-Nutra is its fasting-mimicking technology - essentially a way to hack the body's biology. It's designed to pull the same metabolic levers as a water-only fast, triggering things like autophagy and IGF-1 modulation, but without the safety risks or the sheer misery of actually starving. It's less about 'dieting' and more about precisely re-tuning nutrient-sensing networks to spark cellular repair. The flagship Prolon longevity program, alongside medical nutrition therapies targeting chronic conditions, reflects a reframing that feels quietly radical: food not as fuel alone, nor as wellness theatre, but as programmable intervention. "L-Nutra is a science-backed innovator transforming lives through its pioneering fasting-mimicking products," said Phil Newman, cofounder of the Longevity Show and CEO of Longevity.Technology. "The company works closely with clinics and medical partners worldwide to deliver the proven metabolic health benefits of fasting in a clinically supported way. My family and I have personally experienced the benefits of the Fasting Mimicking Diet, and I'm proud that L-Nutra is supporting our show in bringing this important science and technology to the longevity community and broader public." As health systems strain under the compounding burdens of metabolic dysfunction, oncologic risk and neurodegenerative decline, the notion that nutrition might serve as frontline infrastructure - preventative, therapeutic and economically strategic - is gaining traction. L-Nutra's presence at the Longevity Show is not merely sponsorship; it is signal. A marker of where the field is heading. Food as code. Fasting as platform. Longevity, engineered. To learn more about partnership and exhibitor opportunities at The Longevity Show 2026, contact the Sponsor & Exhibitor team. The Longevity Show opens its doors on 26-27 June 2026 at Tobacco Dock, London. Early bird tickets for all tiers are now available at www.longevityshow.com until 28 February 2026.

L-Nutra raises additional $36.5M in Series D funding. L-Nutra, a Los Angeles, CA-based nutri-technology company advancing science-driven nutrition for longevity and nutrition as medicine, raised additional $36.5M in its Series D funding. The investment was led by Mubadala Investment Company. The company intends to use the funds to expand operations and its development efforts. Led by MD, PhD, Chairman and CEO Joseph Antoun, L-Nutra is a nutri-technology company that focuses on the discovery, design, and commercialization of Nutrition for Longevity and Nutrition as Medicine programs that enhance human healthspan and drive remission in chronic diseases. In partnership with 18 global university research centers, it has developed nutrition formulations inspired by precision nutrition and empowered by cellular longevity science. Supported by 47 clinical trials and 137 granted patents, L-Nutra improves the nutrition's research to treat aging and chronic disease. Its programs, including Prolon for longevity and its medical nutrition therapies for chronic conditions, are designed to optimize safety, nourishment, and therapeutic benefit while implementing health outcomes across populations.